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Sexual Dimorphism in Innate Immunity
George Moxley,1 Danielle Posthuma,2 Patricia Carlson,3 Eloise Estrada,3 Jinfeng Han,1
Linda L. Benson,1 and Michael C. Neale4
Objective. To establish whether variation in in-
nate immunity, as measured by the level of tumor necro-
sis factor (TNF) in lipopolysaccharide (LPS)–stimulated
whole-blood culture, is related to sex or HLA.
Methods. Normal volunteers (72 women, 159
men) completed questionnaires and donated peripheral
blood specimens. Blood samples were exposed to LPS in
a 4-hour in vitro culture, and supernatants were then
tested by sandwich-type immunoassay measuring TNF
levels. Statistical techniques included multivariate ana-
lysis and maximal-likelihood modeling of allelic effects.
Results. Both male and female groups showed
substantial within-group variation (coefficient of varia-
tion 59.1% for women, 40.3% for men). However, the
mean  SD LPS-stimulated TNF level in the female
group was nearly 30% lower than in the male group
(1,556  919 pg/ml versus 2,203  889 pg/ml; P <
0.0001, unadjusted for covariates). Sex was independent
of any microsatellite marker allele of TNF (covariate-
adjusted increment of 785 pg/ml from female to male
sex; P < 0.0001). In multivariate modeling of the female
group, the LPS-stimulated TNF level was not indepen-
dently influenced by menstrual cycle phase, oral contra-
ceptive use, or plasma estradiol level. Allelic modeling
showed that significant TNFab microsatellite allelic
effects existed (P  0.002 versus model omitting allelic
effects). The female group showed a significantly down-
ward deviation from mean TNF level with TNFa4b5
(903 pg/ml deviation from the overall mean) and an
upward deviation with TNFa10b4 (598 pg/ml). The male
group showed significantly higher-than-mean levels
with TNFa1b5 (909 pg/ml), TNFa5b7 (1,191 pg/ml), and
TNFa6b5 (332 pg/ml). Thus, the two sex groups differed
in which of their TNFab marker alleles showed signifi-
cant deviations from the overall mean.
Conclusion. Female subjects have a nearly 30%
lower innate immune response, stemming largely from
influence independent of the HLA-region TNF locus and
without further independent variation stemming from
plasma estrogen level.
Immunity, the ability to resist microbial invasion,
is a paramount function based on diverse mechanisms.
Host defense may stem from physical barriers, phago-
cytes, natural killer cells, and various plasma effector
molecules, such as the complement system. Innate or
natural immunity, a method of host defense represented
among most multicellular living things, is based on
phagocytes and plasma proteins. For example, endotoxin
binds to a plasma protein (lipopolysaccharide [LPS]–
binding protein, or LBP), and the complex in turn binds
to monocyte cell surface receptors and incites an inflam-
matory reaction. This first line of defense is present
before microbial exposure, is immediately active, does
not change with repeated exposure, and is not specific
for the invading foreign material. Another kind of
immunity found only in vertebrates is adaptive or spe-
cific immunity. This kind of host defense develops after
a delay of 4–7 days after exposure and develops speci-
ficity for the invading material; it stems from specific
lymphocytes and immunoglobulins.
Immune responses are sexually dimorphic in type
and degree (for review, see refs. 1 and 2). Overall,
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female experimental animals are more likely to develop
a Th1-type response after exposure to an immunogen or
infectious agent, except during pregnancy, when a Th2
response supercedes. In humans, the immune response
also differs by degree: women develop more vigorous
immunity with higher antibody levels and stronger cell-
mediated immunity. Some have suggested that sex ste-
roids, sexually dimorphic pituitary hormones (prolactin
and growth hormone), or liver-derived insulin-like
growth factor 1 may influence immune responses and
autoimmune disease susceptibility (1).
Rheumatoid arthritis (RA) and a plethora of
other autoimmune inflammatory disorders occur pre-
dominantly in women (3). The clinical phenotype of RA
may differ according to sex: compared with a group of
male subjects with RA, a group of female subjects with
RA less frequently had erosive disease, rheumatoid
nodules, and rheumatoid lung disease, and more often
had reconstructive surgery for RA joint damage and
sicca syndrome (4). Exactly why these sex biases occur is
unknown.
RA is a complex genetic disease. It shows familial
aggregation, increased twin concordance in monozygotic
twins compared with dizygotic twins, and diminished
penetrance, but no recognizable Mendelian pattern of
inheritance (5). The genetic basis of RA probably in-
volves several disease genes, of which at least two are
HLA-region disease susceptibility loci, one recognized
through association with shared-epitope DRB1 alleles
and the other by HLA class III markers (6–13). Recent
genome-wide and candidate-gene studies to detect ge-
netic loci linked with RA have generally confirmed HLA
linkage and implicated several genomic intervals distant
from HLA (12,14–16). Because of high utility stemming
from degree of polymorphism, the microsatellites near
the TNF gene have generally been used to represent the
TNF region. These include microsatellite (GT)n and
(GA)n repeats 3.5 kb upstream to the lymphotoxin-
alpha gene LTA (TNFa and TNFb, respectively) that
are, in turn, near the TNF gene; the TNFa and TNFb
markers form TNFab haplotypes like TNFa2-TNFb1,
abbreviated TNFa2b1 (17,18). The TNFab microsatel-
lite markers have been found to be RA susceptibility
factors independent of the HLA–DRB1 region
(6,7,10,12,13). Sex-related bias applies to RA heredity;
sex influences association of HLA markers with RA
(19,20).
Tumor necrosis factor (TNF) may play a role in
RA risk and pathogenesis. TNF is an HLA class III
region cytokine encoded by a locus between those for
the second component of complement and HLA–B.
TNF may be critical for RA pathogenesis, directly
mediating cartilage and bone damage and amplifying
effects from other proinflammatory cytokines, such as
interleukin-1 (IL-1) and granulocyte–macrophage
colony-stimulating factor (21,22). Experimental thera-
pies directed toward TNF, such as chimeric monoclonal
antibodies or soluble TNF receptors, appear to have
remarkable benefit in RA subjects (23–25).
LPS-stimulated TNF production is an in vitro
assay of innate immunity. This measure has marked
interindividual variation (26,27) stemming in part from
genetic factors. Westendorp and colleagues found in
1997 that the LPS-stimulated TNF level had a broad-
sense heritability of 0.60 in a Dutch population (28).
Jacob and colleagues noted interindividual variation in
the mitogen-stimulated TNF level that was specific for
the stimulus used; although the response level was not
the same with all stimuli, high producers with one
stimulus were high producers with another, and low
producers with one stimulus were low producers with
another (29). The TNF production level was related to
HLA haplotype (29). This in vitro measure of innate
immunity also has substantial pathogenetic implications.
The families of survivors of meningococcal infections
had a profile of higher levels of LPS-stimulated TNF and
lower levels of LPS-stimulated IL-10 than did families of
those who did not survive meningococcal infections (28).
Therefore, to investigate sex and HLA influences
on innate immunity, we examined an in vitro assay,
LPS-stimulated whole-blood culture with subsequent
TNF immunoassay on culture supernatant, for influ-
ences stemming from sex and the HLA-region microsat-
ellite marker, TNFab.
PATIENTS AND METHODS
Subjects. This study was approved by the respective
Institutional Review Boards of Virginia Commonwealth Uni-
versity and the Hunter Holmes McGuire Veterans Affairs
Medical Center (VAMC). We identified 231 normal volun-
teers (159 men, 72 women) from the Virginia Commonwealth
University and McGuire VAMC communities. Demographic
characteristics are listed in Table 1. Following informed con-
sent, volunteers completed a short questionnaire and under-
went peripheral blood venipuncture from 8:00 AM to 10:00 AM.
Blood was introduced into a heparin tube and into a potassium
EDTA tube. The questionnaire included demographic infor-
mation, including age and self-reported ethnicity, listing of
medications (nonsteroidal antiinflammatory drugs [NSAIDs],
oral corticosteroids, or others), and illnesses or exercise within
the previous 72 hours. Cigarette smoking influences the innate
immunity measure employed in this study (30), but of samples
from 59 men and 53 women, only 6 subjects gave this history.
SEXUAL DIMORPHISM IN INNATE IMMUNE RESPONSE 251
Automated blood counts and differential were done using a
commercial cell counter (Gen-S; Coulter, Hialeah, FL).
LPS-stimulated whole-blood culture and TNF immu-
noassay. We used a whole-blood stimulation procedure fol-
lowed by TNF enzyme-linked immunoassay as developed by
van der Linden and colleagues at Leiden (31). The whole-
blood stimulation involves diluting heparinized blood with an
equal volume of RPMI 1640 plus glutamine (Invitrogen,
Carlsbad, CA), adding a dilution of LPS (Sigma, St. Louis,
MO), culturing for 4 hours (5% CO2, 37
oC), and harvesting
supernatant for later immunoassay. Maximal TNF production
occurred with 1,000 ng/ml LPS. We stored the supernatants at
–70oC; despite these conditions, immunoreactive TNF levels
declined 8% over a 1-month period and 27% over 3 months.
Addition of protease inhibitors or glycerol or silanization of
storage tubes did not prevent this decline. With 1, 2, and 3
freeze–thaw cycles, the decrements of detectable TNF were
10%, 17%, and 27%. To correct for storage-related decline, we
adopted the strategies of aliquoting supernatants for –70oC
storage, storing an internal control (with known TNF level)
with each batch of unknowns, and testing an aliquot within 2
weeks.
The sandwich immunoassay used a coating monoclonal
antibody directed toward TNF (R&D Systems, Minneapolis,
MN), followed by a dilution of culture supernatant, then by a
second biotinylated mouse monoclonal anti-TNF antibody
(R&D Systems), then by streptavidin–peroxidase, then by a
solution of tetramethylbenzidine substrate, and finally by a
stop solution (0.25M sulfuric acid). Optical density was mea-
sured at 450 nm using an automated spectrophotometer
(Tecan Spectra Rainbow, Durham, NC). We also optimized
the TNF immunoassay to maximize sensitivity. We examined
the influence of NaCl added to the supernatant just before
immunoassay and found that a final NaCl concentration of
0.225M led to a 16% increment in TNF detected; we reasoned
that this condition might have released TNF from binding
proteins. The intraassay variation for the whole-blood stimu-
lation plus immunoassay was 3.7%, and the interassay variation
over 3 months was 8.2%, both of which were acceptable.
The effects of common over-the-counter and prescrip-
tion medications and diurnal variation are also important. We
examined medication effects: a single 650-mg dose of aspirin
had little effect within 4 hours, and a single 10-mg dose of
prednisone gave 98% suppression of TNF within 2 hours.
Inducible TNF levels increased slightly from 8:00 AM to 11:00
AM (18%); thus, morning sampling during this period does
increase variation slightly. We examined one male internal
control by obtaining 21 different blood samples over a period
of 15 months to examine interassay plus biologic variation
(including NSAID, minor illness, and aerobic exercise effects),
and the mean  SD TNF level was 2,823  533 pg/ml
(coefficient of variation 18.9%).
DNA purification and TNFab genotyping. The potas-
sium EDTA tube was used for DNA purification using the
salting-out method (PureGene kit; Gentra Systems, Minneap-
olis, MN). TNF microsatellites TNFa and TNFb are adjacent
loci 6 kb telomeric to the TNFA locus (National Center for
Biotechnology Information accession no. Z15026) (17,18).
Genotypes were assigned by polymerase chain reaction (PCR)
(17) followed by sequencing-type gel electrophoresis and silver
staining; controls included PCR products from templates
derived from cell lines of known TNF genotype (32,33). We
first typed for TNFa and TNFb microsatellite genotypes. Then,
by amplifying the entire TNFab region, we derived the TNFab
haplotype from the known TNFa and TNFb genotypes and the
TNFab product size (33). For example, in an individual with
TNF genotypes a2,a6 and b1,b5 and TNFab product lengths of
202 bp and 214 bp, we reasoned that the TNFab length was
consistent with haplotypes TNFa2b1 (202 bp) and TNFa6b5
(214 bp), not a2b5 (206 bp) and a6b1 (210 bp). Each TNFab
microsatellite haplotype was treated as an allele for further
analyses.
Statistical analysis. We used SAS System for Windows
(Release 8.01; SAS Institute, Cary, NC) to develop models to
predict the LPS-stimulated whole-blood TNF level (pg/ml) in
normal volunteers based on sex and TNFab markers (each
coded for the number of alleles: 0, 1, or 2), as adjusted for
confounders (age in years, race, NSAIDs within the previous 3
days, oral corticosteroids within the previous 3 days, duration
of sleep the prior night in hours, or illness within the previous
3 days). For example, a simplified equation for all subjects is as
follows: TNF  2,615  (261  NSAIDs)  (612  sex) 
(–551  illness)  (–142  sleep)  (–573  TNFa4b5) 
(–381  TNFa5b5)  (903  TNFa5b7).
Here, the dependent or response variable is the LPS-
stimulated whole-blood TNF level, and the explanatory vari-
ables are sex, 3 TNFab markers, and 3 potential confounding
variables (NSAIDs, illness, and hours of sleep). The numbers
in front of the explanatory variables are regression coefficients
and are interpreted as follows: if NSAIDs, illness, sleep,
TNFa4b5, TNFa5b5, and TNFa5b7 are held constant, then the
LPS-stimulated TNF level increases by 612 pg/ml for male
Table 1. Variables used in multiple linear regression models*
Variable
Women
(n  72)†
Men
(n  159)‡
Continuous
TNF level, mean  SD pg/ml 1,556 919 2,203 889
Age, mean  SD years 30.9  8.2 30.4 8.7
Sleep, mean  SD hours 6.9  1.2 7.0 1.1
Estradiol, mean  SD pg/ml§ 34.6  34.9 NA
Categorical¶
NSAIDs 31/41 36/123
Oral corticosteroids 1/71 1/158
Illness 11/61 11/148
Menstrual cycle phase, no. in
late luteal phase/no. in early
follicular phase
29/39 NA
Oral contraceptive use, no.
currently using/no. not using
33/39 NA
Exercise 35/37 59/23
* TNF  tumor necrosis factor; NA  not applicable; NSAIDs 
nonsteroidal antiinflammatory drugs.
† Includes 55 whites, 8 African Americans, 6 Asians, and 3 of other
ethnic origin.
‡ Includes 118 whites, 9 African Americans, 23 Asians, and 9 of other
ethnic origin.
§ n  51 in this group.
¶ Except for menstrual cycle and oral contraceptives, values are the
number of subjects who have/number who have not, during the
previous 72 hours, taken NSAIDs or oral corticosteroids, experienced
an illness, or engaged in exercise. Sums less than n reflect missing data.
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sex over that for female sex. (Please note that this model
represents a simplified explanatory illustration; the best-fitting
models are incorporated into the Results.)
We analyzed by using multiple linear regression mod-
eling methods to verify the association between the LPS-
stimulated whole-blood TNF level and the explanatory vari-
ables of sex and TNFab markers, while controlling for
confounders (as listed above). The independent variables used
in the full model include those listed in Table 2. We confirmed
the assumptions of multiple linear regression (linearity, equal
variances, independence, and normal distribution of TNF for
each value of explanatory variables). The explanatory variables
were evaluated by PROC REG (SAS System for Windows;
SAS Institute); those variables selected by stepwise linear
regression are shown in bold in Table 2. Potential explanatory
variables were examined and found to have no significant
collinearity by PROC GLM (SAS System for Windows; SAS
Institute); sex did have some trend toward interaction with
TNFa1b5 (P 0.0237) and TNFa10b4 (P 0.0259). We found
no outliers in data for men or women.
Mx modeling of allelic effects. Mx (written by MCN;
available at no charge online at http://www.vipbg.vcu.edu/
mxgui) is a combination of a matrix algebra interpreter and a
numerical optimizer. It enables exploration of matrix algebra
through a variety of operations and functions. There are many
built-in fit functions to enable structural equation modeling
and other types of statistical modeling of data. It offers the
fitting functions found in commercial software such as
LISREL, LISCOMP, EQS, and CALIS, along with facilities
for maximum likelihood estimation of parameters from miss-
ing data structures, under normal theory. Complex “nonstand-
ard” models are easy to specify. For further general applica-
bility, Mx allows users to define their own fit functions, and
optimization may be performed subject to linear and nonlinear
equality or boundary constraints. In the present study, Mx was
used to provide maximum likelihood fit for TNFab marker
allelic effects to actual data in sex-stratified analyses; infre-
quent marker alleles were combined into a single category. To
assess statistical significance, the modeling examined reduction
in model fit when specific marker alleles were dropped. The
potential confounders of age, self-reported race, medications,
sleep, and illness were incorporated into the models.
RESULTS
Demographic features. There were 159 male
subjects and 72 female subjects, of whom 19 women
were not typed for TNFab microsatellites. The male and
female subject groups did not differ significantly in some
potential confounders (hours of sleep, age, frequency of
corticosteroid use, or race) (Table 1). The male group
showed a trend toward reporting illness less frequently
Table 2. Multivariate model for predicting lipopolysaccharide-stimulated TNF level*
No. of alleles†
Coefficient  SE  95% CI P T scoreFemale Male
Intercept 2,130 538 1,043, 3,217 0.0001 3.96
Age 3.5 7.8 12, 19 0.6504 0.45
African American 489 249 992, 14 0.0512 1.96
Asian 156 182 524, 212 0.3937 0.85
NSAIDs 267 143 22, 556 0.0628 1.87
Steroids 87 648 1,396, 1,222 0.8928 0.13
Illness 477 211 903, 51 0.0252 2.26
Sleep 177 53 284, 70 0.0011 3.32
Sex 785 169 444, 1,126 <0.0001 4.63
TNFa1b5 1 6 1,602 888 3,396, 192 0.0703 1.80
TNFa2b1 10 43 259 181 107, 625 0.1532 1.43
TNFa2b3 13 24 192 204 220, 604 0.3490 0.94
TNFa2b5 3 12 67 271 614, 480 0.8047 0.25
TNFa4b5 8 11 285 259 808, 238 0.2720 1.10
TNFa5b5 2 20 145 228 606, 316 0.5248 0.64
TNFa5b7 1 5 1,234 394 438, 2,030 0.0020 3.13
TNFa6b5 13 37 426 189 44, 808 0.0251 2.26
TNFa7b4 4 30 295 195 99, 689 0.1309 1.52
TNFa10b4 19 45 849 259 326, 1,372 0.0012 3.28
TNFa11b4 21 48 326 180 38, 690 0.0713 1.81
TNFa12b4 1 9 217 318 425, 859 0.4963 0.68
Sex by TNFa10b4 706 261 1,233, 179 0.0074 2.71
Sex by TNFa1b5 2,604 948 689, 4,519 0.0066 2.75
* Variables selected as significant by stepwise linear regression are shown in bold. The model has 22 degrees of freedom, an error of 188, and a
corrected total of 210; r2  0.3013, F  3.68, P  0.0001. Coefficient  represents the increment in TNF level for each unit of the independent
variables listed in the Table, SE  is the standard error of , and 95% CI represents the 95% confidence interval for . The obtained r2 represents
the fraction of all TNF variation accounted for by this model, and the F ratio is an overall test of statistical significance for the multivariate model.
See Table 1 for other definitions.
† The number of alleles represents those among 53 women or 159 men; the remaining alleles were grouped as “infrequents” (see Figure 3).
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(P  0.0543, by Fisher’s exact test) and using NSAIDs
less frequently (P  0.003, by Fisher’s exact test).
LPS-stimulated TNF level influenced by sex.
Both male and female groups showed substantial within-
group variation (coefficient of variation 59.1% for
women, 40.3% for men). However, the mean  SD
LPS-stimulated TNF level in the female group was
nearly 30% lower than in the male group (1,556  919
pg/ml versus 2,203 889 pg/ml; P 0.0001, by Wilcoxon
2-sample test). The possibility that this stemmed from a
difference in peripheral blood leukocyte count was
examined in a subset of 31 men and 14 women; there was
no statistically significant difference in mean  SD
absolute monocyte count (49.3  17.2 monocytes/mm3
for women versus 49.6  11.3 monocytes/mm3 for men;
P  0.455, by Wilcoxon 2-sample test) or lymphocyte
count (233.5  95.8 lymphocytes/mm3 for women versus
183.3  54.3 lymphocytes/mm3 for men; P  0.167, by
Wilcoxon 2-sample test).
In both male and female groups, the LPS-
stimulated TNF level correlated with the absolute mono-
cyte count (Pearson’s r  0.382 and Pearson’s r  0.582,
respectively, P  0.05 for each). There was also a
correlation with the absolute lymphocyte count in men
and a trend in women (Pearson’s r 0.386, P 0.05 and
Pearson’s r  0.491, P not significant, respectively).
Regardless of this, however, the mean  SD LPS-
stimulated TNF level was lower in the female group,
whether expressed per 103 leukocytes (198.7  144.3
pg/ml versus 329  138 pg/ml; P  0.006), per 103
monocytes (26.6  19.6 pg/ml versus 49.6  11.2 pg/ml;
P  0.041), or per 103 lymphocytes (5.6  4.0 pg/ml
versus 10.0  4.3 pg/ml; P  0.003) (all by Wilcoxon
2-sample test). To address whether differences in pro-
tease activity might account for the female group–
related decrement, we incubated cell-free supernatants
at 37oC for periods of up to 2 hours, but there was no
decrease in TNF detected. Thus, the lower value in the
female group did not solely reflect an influence on cell
populations or induced proteases; women produced
lower quantities of TNF.
TNFab microsatellite marker genotyping. The
scatter plots of data for both men and women showed
substantial overlap among the values represented for all
alleles (Figures 1 and 2). The frequency distribution of
TNFab markers did not differ significantly between male
and female groups (2 14.5, 8 degrees of freedom [df],
P  0.182).
TNF level predicted by sex independently of
TNFab (Table 2). Multivariate analyses allowed detec-
tion of whether sex was independent of TNFab markers
while controlling for the potential confounders of age,
race, medications, recent illness, or sleep. The results are
shown in Table 2. Sex was a statistically significant
independent variable predictive of the LPS-stimulated
TNF level (P  0.0001); when all other potential con-
founders and independent variables were held constant,
female sex led to a predicted TNF level slightly 800
pg/ml lower than male sex (Table 2). In sex-stratified
Figure 1. Lipopolysaccharide-stimulated tumor necrosis factor (TNF)
levels represented among 159 healthy normal male subjects. Each
circle represents a value for an individual, with the specific TNFab
marker indicated on the bottom of the figure. Heterozygotes are
represented as two circles, one for each TNFab marker, while homozy-
gotes are represented as two circles for a single TNFab marker.
Overlapping values are represented as overlapping circles.
Figure 2. Lipopolysaccharide-stimulated TNF levels represented
among 72 healthy normal female subjects. Each circle represents a
value for an individual, with the specific TNFab marker indicated on
the bottom of the figure. Heterozygotes are represented as two circles,
one for each TNFab marker, while homozygotes are represented as
two circles for a single TNFab marker. Overlapping values are
represented as overlapping circles. See Figure 1 for definitions.
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linear regression analyses with stepwise selection with
main effects only, the female model included TNFa1b5,
TNFa4b5, and TNFa10b4 with P values of 0.05. The
corresponding male model selected TNFa1b5,
TNFa5b7, TNFa6b5, and TNFa11b4. However, the
TNFa1b5 coefficients for women and men differed: the
coefficient for women was highly negative (mean  SE
2,466  963 pg/ml), the corresponding coefficient for
men was positive (mean  SE 1,102  400 pg/ml), and
the two confidence intervals did not overlap.
Stepwise selection employing the model using
men and women together, as outlined in Table 2,
selected only sex (P  0.0001 in the reduced model),
TNFa4b5 (P  0.0131), TNFa5b7 (P  0.0233), and sex
by TNFa1b5 (P  0.0396), but not the interaction term
of sex by TNFa10b4. The r2 represented in Table 2 is the
fraction of all TNF variation accounted for by this
model, 30%; thus, much variation remains uncaptured
by the included variables.
TNFab marker allelic effects on LPS-stimulated
TNF level. Modeling of allelic effects for each TNFab
marker allele allowed testing of significant deviations
from the overall means for the female or the male
groups while controlling for the covariates of age, race,
medications, illness, and sleep. Dominance effects did
not fit as well as additive model effects. The overall
modeling showed that there were significant TNFab
marker allelic effects (comparison of full model versus
model with no TNFab allelic effects: 2  44.8, 19 df,
P 0.002). With the model showing the best fit, allowing
different allelic means for each sex group, the female
group showed negative deviation from the mean for
TNFa4b5 and positive deviation with TNFa10b4 (Table
3 and Figure 3). For the male group, higher-than-mean
levels were found with TNFa1b5, TNFa5b7, and
TNFa6b5 (Table 3 and Figure 3).
The multiple linear regression model represented
in Table 2 showed a significant coefficient for an inter-
action term of sex with TNFa1b5 and sex with
TNFa10b4, but stepwise selection removed the sex with
TNFa10b4 variable. Thus, both regression and modeling
of allelic effects suggested that some TNFab marker
effects may differ between male and female groups. In
allelic effects models, covariates accounted for only a
small fraction of variation (8% in women, 2% in men),
while TNFab marker allele effects conferred substan-
tially more of the variation (23% in the female group,
17% in the male group). Thus, while the sex influence on
the LPS-stimulated TNF level is largely exerted outside
TNFab, TNFab itself does account for substantial vari-
ation, with different TNFab marker alleles conferring
statistically significant deviations from the mean for each
sex group.
Consideration of estrogen effects. The possibility
that TNF measures reflected estrogen effects was exam-
ined by obtaining blood samples from 10 normal female
volunteers twice during a menstrual cycle. There was no
trend toward lower or higher levels during the luteal
phase of the menstrual cycle. A subset of 51 female
subjects had estradiol levels measured. TNF did not
correlate significantly with the plasma estradiol level
(Pearson’s r  0.148, P  0.30). Using multivariate
analytic methods (similar to those reflected in Table 2,
but including only TNFa1b5, TNFa4b5, TNFa10b4, and
TNFa11b4), estradiol levels and variables representing
oral contraceptive use and menstrual cycle phase did not
influence the TNF level (P  0.266, P  0.870, and P 
0.404, respectively; data not shown) or interact with
TNFab marker alleles (data not shown).
Table 3. Influence of individual TNFab marker alleles on
lipopolysaccharide-stimulated TNF level*
Allelic effects
Deviation
from mean,
pg/ml† 95% CI
Female‡
Infrequent alleles 44.3 95.7, 186.8
TNFa2b1 37.4 522.5, 622.9
TNFa2b3 440.2 996.2, 133.1
TNFa4b5 903.0 1,606.4, 152.9
TNFa6b5 157.4 648.6, 350.0
TNFa10b4 597.9 135.0, 1,083.3
TNFa11b4 289.1 178.4, 772.2
Male‡
Infrequent alleles 122.8 300.9, 55.6
TNFa1b5 908.6 247.5, 1,595.2
TNFa2b1 128.3 155.4, 420.3
TNFa2b3 111.5 260.9, 494.5
TNFa2b5 383.8 890.5, 145.7
TNFa4b5 277.2 823.3, 296.5
TNFa5b5 297.6 684.2, 104.7
TNFa5b7 1,191.3 473.4, 1,962.2
TNFa6b5 332.1 4.9, 670.4
TNFa7b4 205.4 108.3, 529.0
TNFa10b3 401.4 1,362.4, 640.3
TNFa10b4 9.1 279.0, 305.5
TNFa11b4 241.0 48.5, 540.4
TNFa12b4 74.7 487.6, 671.2
* Comparison of full model versus model with no TNFab allelic
effects: 2  44.8, 19 degrees of freedom, P  0.002. Effects with P
values less than 0.05 are shown in bold. 95% CI  95% confidence
interval (see Table 1 for other definitions).
† Grand mean for women  2,792.2  (838.4  Asian race) 
(164.9  hours of sleep)  (378.2  illness). Grand mean for
men  2,513.5  (6.25  years of age)  (99.9  hours of sleep).
‡ Eight percent of variation among women was accounted for by Asian
race, age, and sleep; 23% was accounted for by TNFab allelic effects.
Two percent of variation among men was accounted for by age and
sleep; 17% was accounted for by TNFab allelic effects.
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DISCUSSION
Taken as a whole, this in vitro measure of innate
immunity, the LPS-stimulated TNF level, varies remark-
ably. Some detectable variation stems from the HLA
region (as reflected in TNFab microsatellite marker
alleles), a large fraction is environmental/random varia-
tion (as reflected in the repeated measures of an internal
control), and another large fraction is associated with
sex and is not directly related to estradiol levels among
premenopausal women. Judging from the model repre-
sented in Table 2, the sum of TNFab markers, sex,
interaction terms, and the potential confounders (age,
race, NSAID use, corticosteroid use, illness, and sleep)
accounts for only 30% of all LPS-stimulated TNF vari-
ation. Thus, while substantial nongenetic variation exists
(as shown by the 19% coefficient of variation in the
internal control), much variation is not accounted for,
particularly in female subjects. One can only speculate
about sources of nongenetic variation at this time, but
exposure to ultraviolet radiation, unreported minor ill-
nesses, environmental exposures, and seasonal varia-
tions may bear examination as potential sources. Exam-
ining why variation occurs may help explain differences
in the threshold for disease or differences in clinical
phenotype and potentially might address differences in
therapeutic responses.
It is not known why the female group had lower
levels of LPS-stimulated TNF. One possibility is an
influence on the hypothalamic–pituitary–adrenal axis. In
previous studies of physiologic corticosteroid doses ad-
ministered to normal volunteers, LPS-stimulated TNF
levels were suppressed (34). Also, LPS-stimulated TNF
levels were lower in morning samples than in afternoon
samples, a pattern inverse to that of cortisol levels (34).
While our morning sampling minimized this diurnal
variation, this finding suggests that any variation in
plasma cortisol level, whether genetic, sex-influenced, or
nongenetic, may affect this measure of innate immunity.
There exists a sexual dimorphism in cortisol response to
endogenous adrenocorticotropic hormone (ACTH); al-
though equivalent daily cortisol secretion is attained,
female subjects have lower ACTH secretion levels,
suggesting more response from the female adrenal cor-
tex (35). Whether the sex-related difference in LPS-
stimulated TNF reflects such an endocrine dimorphism
remains to be determined.
Another potential explanation is a sexual dimor-
phism influencing LPS-stimulated signaling. One might
speculate that the LPS-signaling pathway molecules
(such as LBP, MD-2, CD14, Toll-like receptor 4, myeloid
differentiation primary response gene 88, or IL-1 receptor–
associated kinase 1) might be influenced by sexually dimor-
phic hormones, or that such hormones influence TNF
messenger RNA stability factors. Yet other explanations
might lie in TNF signaling pathways.
That women differ from men in their LPS-
stimulated TNF level is not an entirely novel finding.
Jacob and colleagues had noted that premenopausal
women had more variation than men upon repeated
sampling (29), while postmenopausal female subjects
seemed to have less variation and a mean level more
nearly like that of male subjects. Their study did not find
a sex-related difference in level, but the magnitude of
difference found in the present study would not have
been discerned with the number of previously examined
subjects (29). The present study adds the observations of
magnitude of difference and apparent absence of rela-
tion to menstrual cycle phase, oral contraceptive use, or
estradiol level in female subjects.
This degree of variation may be important. Ex-
perimental animals genetically engineered to lack a
functional TNF pathway, say, by knocking out one or
both TNF receptors, have a propensity toward infections
with Listeria monocytogenes, and those overexpressing
TNF may develop an ileitis similar to Crohn’s disease
Figure 3. Deviations from mean allelic values, with standard error
bars, for each TNFab marker as derived from the best-fitting Mx
model (see Patients and Methods). Equations used to derive grand
means for male and female subjects are represented in Table 3. See
Figure 1 for definitions.
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and also inflammatory arthritis (for review, see ref. 36).
In humans, cerebral malaria is associated with high TNF
levels and with a TNF promoter allele,308A, known to
occur on the TNFa2b3 haplotype (37). Survival of male
subjects with surgery-related sepsis may be influenced by
a TNF-region polymorphic marker (38).
This study is only the latest of several showing
variation of TNF level stemming from HLA-region
influences (for a recent review, see ref. 39), but it does
have the advantages of larger numbers and model-fitting
analyses. Santamaria and colleagues found high in vitro
secretion levels with DR2/DR3 heterozygotes and low
levels with DR3/DR4 heterozygotes (40). Jacob and
colleagues found stable interindividual differences in
stimulated TNF production that were associated with
HLA–DR serologic markers: high levels with DR3 or
DR4 and low levels with DR2 (29). In 87 Dutch male
subjects, Pociot and colleagues found that the TNF level
reflected HLA influence: high TNF levels were associ-
ated with TNFa2, DR3, and DR4, and low levels with
TNFa6, DR2, and DR5 (41). These effects were not
discernable in our male study subjects, but the previous
studies did not correct for covariates or fit models of
allelic effects. Garcia-Merino and colleagues found that
the TNFab marker a2b3 on the ancestral B8–DR3
haplotype was associated with higher TNF secretion
levels than was the TNFa11b4 marker on a B7–DR2
haplotype (42). Investigators at Leiden have described up
to 4-fold differences in stimulated TNF levels among
families that could not be attributed to TNF promoter
polymorphism differences (43); there was a slightly lower
TNF level associated with the –238GA promoter genotype.
Thus, several groups of investigators have found
HLA-region influences on stimulated TNF production,
but the details vary and are probably related to differ-
ences in ancestral haplotypes according to the popula-
tion studied. However, previous studies have addressed
allelic effects either by comparing homozygous HLA
genotypes (42) or by comparing subjects positive for one
or another HLA haplotype (29), in effect partly ignoring
the contribution of the second HLA haplotype. Model
fitting allows better analyses of allelic effects, and from
the present study, it appears that TNFab allelic effects
are additive.
How LPS-stimulated TNF production as an in
vitro measure of innate immunity relates to the genetics
of RA remains to be clarified. The HLA region appears
to contain at least two disease-risk genes, one encoded
by shared-epitope DRB1 polypeptide chains (44) and
the other within the class III region and recognized
through independent association with markers such as
TNFa2b1 in men and TNFa2b3 and TNFa6b5 in women
(6,7,13). While some TNFab marker alleles caused
significant deviations from the mean TNF level (Figure
3), from the present study one would not immediately
discern a difference in LPS-stimulated TNF production
for TNFa2b1 in men or for TNFa2b3 or TNFa6b5 in
women. However, the present study does not directly
address functional effects from ancestral HLA haplo-
types (45) that might occur in disease-relevant tissues.
Thus, findings of this study are consistent with
the notion that variation in this in vitro measure of
innate immunity, LPS-stimulated TNF production, may
be partitioned into substantial sex-related variation in-
dependent of HLA, HLA-region variation with some
discernable superimposed sex-related effects, and varia-
tion due to unknown factors. While there is detectable
HLA-related influence, the vast majority of variation stems
from other sources, and some of this variation may influ-
ence the threshold for developing autoimmune disease.
ACKNOWLEDGMENT
The authors are indebted to the McGuire VAMC and
Virginia Commonwealth University communities for recruit-
ing and enlisting volunteer subjects.
REFERENCES
1. Whitacre CC, Reingold SC, O’Looney PA. A gender gap in
autoimmunity. Science 1999;283:1277–8.
2. Whitacre CC, Blankenhorn E, Brinley FJ, Collier E, Duquette P,
Fox H, et al. Sex differences in autoimmune disease: focus on
multiple sclerosis [serial online]. 1999; Accessed October 15, 2001.
URL: www.sciencemag.org/feature/data/983519.shl.
3. Beeson PB. Age and sex associations of 40 autoimmune diseases.
Am J Med 1994;96:457–62.
4. Weyand CM, Schmidt D, Wagner U, Goronzy JJ. The influence of
sex on the phenotype of rheumatoid arthritis. Arthritis Rheum
1998;41:817–22.
5. Silman A, Hochberg M. Rheumatoid arthritis. In: Silman A,
Hochberg M, editors. Epidemiology of the rheumatic diseases.
Oxford: Oxford University Press; 1993. p. 7–68.
6. Mulcahy B, Waldron-Lynch F, McDermott MF, Adams C, Amos
CI, Zhu DK, et al. Genetic variability in the tumor necrosis
factor-lymphotoxin region influences susceptibility to rheumatoid
arthritis. Am J Hum Genet 1996;59:676–83.
7. Hajeer A, John S, Ollier WE, Silman AJ, Dawes P, Hassell A, et
al. Tumor necrosis factor microsatellite haplotypes are different in
male and female patients with RA. J Rheumatol 1997;24:217–9.
8. Ota M, Katsuyama Y, Kimura A, Tsuchiya K, Kondo M, Naruse T,
et al. A second susceptibility gene for developing rheumatoid
arthritis in the human MHC is localized within a 70-kb interval
telomeric of the TNF genes in the HLA class III region. Genomics
2001;71:263–70.
9. Zanelli E, Jones G, Pascual M, Eerligh P, Van der Slik AR,
Zwinderman AH, et al. The telomeric part of the HLA region
predisposes to rheumatoid arthritis independently of the class II
loci. Hum Immunol 2001;62:75–84.
10. Hajeer AH, Dababneh A, Makki RF, Thomson W, Poulton K,
Gonza´lez-Gay MA, et al. Different gene loci within the HLA-DR
SEXUAL DIMORPHISM IN INNATE IMMUNE RESPONSE 257
and TNF regions are independently associated with susceptibility
and severity in Spanish rheumatoid arthritis patients. Tissue
Antigens 2000;55:319–25.
11. Singal DP, Li J, Zhu Y. HLA class III region and susceptibility to
rheumatoid arthritis. Clin Exp Rheumatol 2000;18:485–91.
12. Martı´nez A, Ferna´ndez-Arquero M, Pascual-Salcedo D, Conjero
L, Alves H, Balsa A, et al. Primary association of tumor necrosis
factor-region genetic markers with susceptibility to rheumatoid
arthritis. Arthritis Rheum 2000;43:1366–70.
13. Meyer JM, Han J, Moxley G. Tumor necrosis factor markers show
sex-influenced association with rheumatoid arthritis. Arthritis
Rheum 2001;44:286–95.
14. Cornelis F, Faure S, Martinez M, Prud’Homme JF, Fritz P, Dib C,
et al. New susceptibility locus for rheumatoid arthritis suggested by
a genome-wide linkage study. Proc Natl Acad Sci U S A 1998;95:
10746–50.
15. Jawaheer D, Seldin MF, Amos CI, Chen WV, Shigeta R, Monteiro
J, et al. A genomewide screen in multiplex rheumatoid arthritis
families suggests genetic overlap with other autoimmune diseases.
Am J Hum Genet 2001;68:927–36.
16. Bali D, Gourley S, Kostyu DD, Goel N, Bruce I, Bell A, et al.
Genetic analysis of multiplex rheumatoid arthritis families. Genes
Immun 1999;1:28–36.
17. Jongeneel CV, Briant L, Udalova IA, Sevin A, Nedospasov SA,
Cambon-Thomsen A. Extensive genetic polymorphism in the
human tumor necrosis factor region and relation to extended HLA
haplotypes. Proc Natl Acad Sci U S A 1991;88:9717–21.
18. Nedospasov SA, Udalova IA, Kuprash DV, Turetskaya RL. DNA
sequence polymorphism at the human tumor necrosis factor
(TNF) locus: numerous TNF/lymphotoxin alleles tagged by two
closely linked microsatellites in the upstream region of the lym-
photoxin (TNF-beta) gene. J Immunol 1991;147:1053–9.
19. Jaraquemada D, Ollier W, Awad J, Young A, Silman A, Roitt IM,
et al. HLA and rheumatoid arthritis: a combined analysis of 440
British patients. Ann Rheum Dis 1986;45:627–36.
20. Meyer JM, Han J, Singh R, Moxley G. Sex influences on the
penetrance of HLA shared-epitope genotypes for rheumatoid
arthritis. Am J Hum Genet 1996;58:371–83.
21. Brennan FM, Maini RN, Feldmann M. TNF alpha: a pivotal role
in rheumatoid arthritis? Br J Rheumatol 1992;31:293–8.
22. Arend WP, Dayer JM. Inhibition of the production and effects of
interleukin-1 and tumor necrosis factor  in rheumatoid arthritis.
Arthritis Rheum 1995;38:151–60.
23. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen
JS, et al. Randomised double-blind comparison of chimeric mono-
clonal antibody to tumour necrosis factor alpha (cA2) versus
placebo in rheumatoid arthritis. Lancet 1994;344:1105–10.
24. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleisch-
mann RM, Weaver AL, et al. Treatment of rheumatoid arthritis
with a recombinant human tumor necrosis factor receptor
(p75)-Fc fusion protein. N Engl J Med 1997;337:141–7.
25. Rankin EC, Choy EH, Kassimos D, Kingsley GH, Sopwith AM,
Isenberg DA, et al. The therapeutic effects of an engineered
human anti-tumour necrosis factor alpha antibody (CDP571) in
rheumatoid arthritis. Br J Rheumatol 1995;34:334–42.
26. Molvig J, Baek L, Christensen P, Manogue KR, Vlassara H, Platz
P, et al. Endotoxin-stimulated human monocyte secretion of interleu-
kin 1, tumour necrosis factor alpha, and prostaglandin E2 shows
stable interindividual differences. Scand J Immunol 1988;27:705–16.
27. Endres S, Cannon JG, Ghorbani R, Dempsey RA, Sisson SD,
Lonnemann G, et al. In vitro production of IL 1 beta, IL 1 alpha,
TNF and IL2 in healthy subjects: distribution, effect of cyclooxy-
genase inhibition and evidence of independent gene regulation.
Eur J Immunol 1989;19:2327–33.
28. Westendorp RG, Langermans JA, Huizinga TW, Elouali AH,
Verweij CL, Boomsma DI, et al. Genetic influence on cytokine
production and fatal meningococcal disease. Lancet 1997;349:170–3.
29. Jacob CO, Fronek Z, Lewis GD, Koo M, Hansen JA, McDevitt
HO. Heritable major histocompatibility complex class II-associ-
ated differences in production of tumor necrosis factor alpha:
relevance to genetic predisposition to systemic lupus erythemato-
sus. Proc Natl Acad Sci U S A 1990;87:1233–7.
30. Yamaguchi E, Itoh A, Furuya K, Miyamoto H, Abe S, Kawakami
Y. Release of tumor necrosis factor-alpha from human alveolar
macrophages is decreased in smokers. Chest 1993;103:479–83.
31. Van der Linden MW, Huizinga TW, Stoeken DJ, Sturk A,
Westendorp RG. Determination of tumour necrosis factor-alpha
and interleukin-10 production in a whole blood stimulation sys-
tem: assessment of laboratory error and individual variation.
J Immunol Methods 1998;218:63–71.
32. Udalova IA, Nedospasov SA, Webb GC, Chaplin DD, Turetskaya
RL. Highly informative typing of the human TNF locus using six
adjacent polymorphic markers. Genomics 1993;16:180–6.
33. Monos DS, Kamoun M, Udalova IA, Csanky E, Cizman B,
Turetskaya RL, et al. Genetic polymorphism of the human tumor
necrosis factor region in insulin-dependent diabetes mellitus:
linkage disequilibrium of TNFab microsatellite alleles with HLA
haplotypes. Hum Immunol 1995;44:70–9.
34. DeRijk R, Michelson D, Karp B, Petrides J, Galliven E, Deuster
P, et al. Exercise and circadian rhythm-induced variations in
plasma cortisol differentially regulate interleukin-1 beta (IL-1
beta), IL-6, and tumor necrosis factor-alpha (TNF alpha) produc-
tion in humans: high sensitivity of TNF alpha and resistance of
IL-6. J Clin Endocrinol Metab 1997;82:2182–91.
35. Roelfsema F, van den Berg G, Frolich M, Veldhuis JD, van Eijk A,
Buurman MM, et al. Sex-dependent alteration in cortisol response
to endogenous adrenocorticotropin. J Clin Endocrinol Metab
1993;77:234–40.
36. Kollias G, Douni E, Kassiotis G, Kontoyiannis D. On the role of
tumor necrosis factor and receptors in models of multiorgan
failure, rheumatoid arthritis, multiple sclerosis and inflammatory
bowel disease. Immunol Rev 1999;169:175–94.
37. McGuire W, Hill AV, Allsopp CE, Greenwood BM, Kwiatkowski
D. Variation in the TNF-alpha promoter region associated with
susceptibility to cerebral malaria. Nature 1994;371:508–10.
38. Schroder J, Kahlke V, Book M, Stuber F. Gender differences in
sepsis: genetically determined? Shock 2000;14:307–10.
39. Hajeer AH, Hutchinson IV. TNF-alpha gene polymorphism: clinical
and biological implications. Microsc Res Tech 2000;50:216–28.
40. Santamaria P, Gehrz RC, Bryan MK, Barbosa JJ. Involvement of
class II MHC molecules in the LPS-induction of IL-1/TNF secre-
tions by human monocytes: quantitative differences at the poly-
morphic level. J Immunol 1989;143:913–22.
41. Pociot F, Briant L, Jongeneel CV, Molvig J, Worsaae H, Abbal M,
et al. Association of tumor necrosis factor (TNF) and class II major
histocompatibility complex alleles with the secretion of TNF-alpha
and TNF-beta by human mononuclear cells: a possible link to
insulin-dependent diabetes mellitus. Eur J Immunol 1993;23:224–31.
42. Garcia-Merino A, Alper CA, Usuku K, Marcus-Bagley D, Lincoln
R, Awdeh Z, et al. Tumor necrosis factor (TNF) microsatellite
haplotypes in relation to extended haplotypes, susceptibility to
diseases associated with the major histocompatibility complex and
TNF secretion. Hum Immunol 1996;50:11–21.
43. Bouma G, Crusius JB, Oudkerk PM, Kolkman JJ, von Blomberg
BM, Kostense PJ, et al. Secretion of tumour necrosis factor alpha
and lymphotoxin alpha in relation to polymorphisms in the TNF
genes and HLA-DR alleles: relevance for inflammatory bowel
disease. Scand J Immunol 1996;43:456–63.
44. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothe-
sis: an approach to understanding the molecular genetics of suscep-
tibility to rheumatoid arthritis. Arthritis Rheum 1987;30:1205–13.
45. Degli-Esposti MA, Leaver AL, Christiansen FT, Witt CS, Abra-
ham LJ, Dawkins RL. Ancestral haplotypes: conserved population
MHC haplotypes. Hum Immunol 1992;34:242–52.
258 MOXLEY ET AL
